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ABSTRACT
Introduction
Complaints of a dry mouth (xerostomia) and sialoadenitis are frequent side effects of radioiodine 
treatment in differentiated thyroid cancer (DTC) patients. However, detailed prospective data on 
alterations in salivary gland functioning after radioiodine treatment (131I) are scarce. Therefore, the 
primary aim of this study was to prospectively assess the effect of high-activity radioiodine treatment 
on stimulated whole saliva flow rate. Secondary aims were to study unstimulated whole and stimulated 
glandular (i.e., parotid and submandibular) saliva flow rate and composition alterations, development 
of xerostomia, characteristics of patients at risk for salivary gland dysfunction, and whether radioiodine 
uptake in salivary glands on diagnostic scans correlates to flow rate alterations. 
Methods
In a multicenter prospective study, whole and glandular saliva were collected both before and five 
months after radioiodine treatment. Furthermore, patients completed the validated xerostomia inventory 
(XI). Alterations in salivary flow rate, composition and XI score were analyzed. Salivary gland radioiodine 
uptake on diagnostic scans was correlated with saliva flow rate changes after radioiodine treatment. 
Results
Sixty-seven patients (mean age 48 ± 17 years, 63% female, 84% underwent ablation therapy) completed 
both study visits. Stimulated whole saliva flow rate decreased after ablation therapy (from 0.92 
[IQR 0.74 - 1.25] to 0.80 [0.58 - 1.18] ml/min, p = 0.003), as well as unstimulated whole- and stimulated 
glandular flow rates (p < .05). The concentration of salivary electrolytes was similar at both study visits, 
whereas the output of proteins, especially amylase (p < 0.05), was decreased. The subjective feeling of dry 
mouth increased (p = 0.001). Alterations in saliva flow rate were not associated with (semi)-quantitatively 
assessed radioiodine uptake in salivary glands on diagnostic scans. For the small cohort of patients 
undergoing repeat radioiodine therapy, we could not demonstrate alterations in salivary parameters.
Conclusion
We prospectively showed that salivary gland function is affected after high-activity radioiodine ablation 
therapy in patients with DTC. Therefore, more emphasis should be placed on salivary gland dysfunction 
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INTRODUCTION
Thyroid cancer is a common endocrine malignancy with 62,450 expected cases in the United States for 
2015, and is currently estimated to be the fifth most common cancer in women.1 Differentiated thyroid 
carcinoma (DTC), covering the papillary and follicular subtypes, is the most common malignancy of the 
thyroid. Patients with DTC have a favorable survival, which is presumably due to the relative indolent 
nature of the disease combined with an effective treatment consisting of a (near)-total thyroidectomy, 
radioiodine (131I) treatment and thyroid hormone suppression therapy. Adverse effects of treatment are 
increasingly being recognized, amongst them radioiodine-induced salivary gland damage.2 
 The adverse effect of radioiodine on salivary glands is presumed to be related to the ability of salivary 
glands to concentrate (radio)iodine. This ability is probably facilitated by the sodium-iodide symporter, 
which is especially expressed in the striated ducts of the gland.3 Primary saliva is produced in the acini 
of the salivary glands and subsequently drains into the intercalated, striated and excretory ducts. During 
the transport in the ductal system, the composition of saliva is actively changed, e.g., sodium and 
chloride are reabsorbed, and potassium is excreted into the saliva. As radioiodine is mainly concentrated 
in the ductal system, the beta radiation may generate luminal debris which may cause ducts to narrow.4 
These processes can lead to obstruction of the ductal system, causing an inflammatory response in the 
secretory tissue (sialoadenitis), and glandular degeneration.5 Moreover, salivary gland stem cells, that 
have been proposed to mainly reside in the excretory ducts,6 may be affected due to the exposure to 
beta radiation resulting in a reduced regenerative potential.2
 Sialoadenitis can cause complaints of pain and swelling, and result in an altered saliva composition. 
Ongoing sialoadenitis can lead to atrophy of the secretory parenchyma and salivary gland fibrosis, which 
may result in decreased saliva flow rates (hyposalivation), sensation of a dry mouth (xerostomia) and an 
increased risk of oral infections and dental caries.7 A further loss of salivary gland function due to stem 
cell damage may become clinically manifest after 60 - 120 days, as this time is specific for salivary cell 
turnover.8
 Previous studies focused on oral complaints that occur in roughly 30% of patients,9-11 and assessment 
of salivary gland function by technetium-99m salivary scintigraphy.12,13 Detailed, prospective data on 
salivary gland function by measurement of whole and/or glandular saliva flow rates (sialometry) 
including analysis of saliva composition (sialochemistry) are scarce for DTC patients.14 When such data 
are available, these may provide us with detailed knowledge on the effects of radioiodine treatment on 
salivary gland function. 
 The primary aim of this study was to assess the effect of high-activity radioiodine treatment on 
stimulated whole saliva flow rate when the acute effect has passed. Secondary aims were to study 
unstimulated whole- and stimulated glandular saliva flow rate and composition, as well as xerostomia 
alterations after radioiodine treatment. Furthermore, we aimed to identify characteristics of patients at 
risk for salivary gland dysfunction, and study whether radioiodine uptake in salivary glands as assessed 
on diagnostic scintigraphic and SPECT/CT scans correlates with post-therapy salivary gland dysfunction 
in radioiodine-treated DTC patients.
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PATIENTS AND METHODS
Design and study population
We performed a multicenter prospective study in the three centers in the north of The Netherlands 
where patients with DTC are treated with radioiodine; the University Medical Center Groningen, Isala 
Clinics Zwolle and the Medical Center Leeuwarden. The study was approved by the institutional ethics 
committee (METc 2013.039), and was registered at The Netherlands National Trial Register (NTR4354). All 
patients provided written informed consent.
 All consecutive patients of at least 18 years old with DTC who were scheduled for radioiodine ablation 
(i.e. treatment targeting remnant normal thyroid tissue post-thyroidectomy) or repeat high-activity 
radioiodine treatment, were asked to participate in this study. Exclusion criteria were a history of Sjögren’s 
syndrome or another salivary gland disease affecting baseline salivary gland function, oral ulceration, 
and radioiodine treatment preparation with recombinant human thyroid-stimulating hormone (rhTSH). 
Preparation with rhTSH was chosen as an exclusion criterion to ensure a homogeneous patient population, 
and, moreover, the side effects of endogenous TSH stimulation are probably more profound. Included 
patients were scheduled for two study visits: the first at least one week before radioiodine treatment, 
and the second approximately five months after treatment. The latter was chosen because after five 
months the acute phase has passed, but patients are not yet scheduled for another radioiodine therapy, 
if necessary. At both study visits, whole and glandular saliva were collected, and patients completed a 
validated xerostomia inventory (XI) containing 11 multiple-choice questions related to xerostomia.15 In 
addition, data were collected on patient characteristics, see supplemental data.
Treatment and follow-up
Patients were treated according to the Dutch thyroid carcinoma guideline,16 see supplemental data. 
In general, treatment included a (near)-total thyroidectomy with a central or lateral neck lymph node 
dissection if indicated. Four to six weeks after surgery, radioiodine ablation therapy was applied, usually 
with an activity of 3.7 - 5.5 GBq, depending on the risk stratification. All radioiodine therapies were 
performed under endogenous TSH stimulation, and patients were prescribed an iodine restricted diet one 
week prior to the radioiodine treatment. Patients were advised to drink plenty of water, and regularly use 
chewing gum or sour candies after administration of radioiodine therapy. No further recommendations 
about the time point of initiation, frequency, and duration of salivary gland stimulation were made, and 
no other salivary gland protection measured were applied. 
 
Saliva collection
During the two study visits, whole and glandular saliva were collected using standardized methods 
(see Supplemental Data). Unstimulated whole saliva was collected during five minutes by regularly 
spitting in a container. Thereafter, paraffin-stimulated whole saliva was collected in a similar fashion 
during five minutes. During the glandular saliva collection, saliva of the left and right parotid, and the 
submandibular/sublingual glands (later referred to as submandibular saliva) were separately collected 
for ten minutes. The salivary glands were stimulated by applying a cottonwool swab with 2% citric acid 
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Sialochemistry
Sodium and potassium were quantified using atomic emission spectrometry (Thermo Fisher Scientific, 
Inc). Chloride, amylase, and total protein were measured using a Roche Modular analyzer (Roche, 
Mannheim, Germany), see supplemental data. 
Imaging protocol
Planar whole body imaging was performed 24 hours after administration of 40 MBq radioiodine (131I) 
before ablation planning, or 72 hours after administration of 74 MBq radioiodine (131I) for planning of repeat 
treatment. Post-therapy whole body scans (WBS) were acquired 7 days after high-activity radioiodine 
(131I) administration. SPECT/CT imaging of the head and neck was performed immediately after the post-
therapy WBS, see supplemental data.
  
Iodine uptake measurement on diagnostic scans
Iodine uptake in both parotid and submandibular glands was scored semi-quantitatively on 
the planar pre- and post-therapy WBS. Furthermore, radioiodine uptake in the salivary glands was 
quantified on the post-therapy SPECT/CT scan. The radioiodine activity concentrated in each gland was 
expressed in Bq and Bq/ml, see supplemental data. 
 
Statistical analyses
Data are presented as numbers (percentages), medians with inter quartile ranges (IQR), or means with 
standard deviation, as appropriate. Data were analyzed separately for patients who underwent ablation 
and repeat radioiodine treatment. Paired salivary flow rates (i.e., when both pre-and post-treatment 
measurements were available of a particular gland in the same individual) were compared using the 
Wilcoxon signed rank test. In case gland dysfunction was observed at baseline, or when oral anatomy 
did not allow parotid saliva collection (of which a note was taken during measurement), the patient 
was excluded from the analysis with regard to the corresponding flow-rate, see supplemental data. 
Alterations in saliva composition and XI scores were tested using the Wilcoxon signed rank-test for paired 
data. 
 We analyzed differences between patients (age, sex, TNM stage, tumor histology, and cumulative 
radioiodine activity) who did, or did not have a decrease of at least 50% in stimulated whole saliva flow 
rate using the chi-squared test, t-test and non-parametric tests, as appropriate, see supplemental data.
 Correlations between XI scores and the primary outcome parameter, and between radioiodine uptake 
in parotid and submandibular glands and sialometry measures were tested using Spearman’s rho. 
 All tests were two-sided, and a p-value < 0.05 was considered statistically significant. A Bonferroni 
corrected alpha for multiple testing was used for analysis of individual XI questions. IBM SPSS for Windows 
(version 22.0) was used for all analyses.
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RESULTS
Patients
Ninety-five patients were approached for study participation, of whom 75 patients consented and were 
included in the study (Figure 1). Eight patients were excluded, due to cancellation of treatment (n = 7) 
or a change in radioiodine therapy preparation, from endogenous TSH stimulation to rhTSH (n = 1). The 
remaining 67 patients (of whom 56 underwent ablation, and 11 repeat radioiodine therapy) completed 
both study visits. Mean age of these patients was 47.7 ± 17.1 years. Forty-two (63%) patients were female 
(Table 1). An overview of the numbers of paired saliva measurements available for analysis is provided in 
Supplemental Figure 1.
95 patients were approached 
for study participation
15 patients refused participation, and 
in 5 patients study participation was 
logistically not feasible
75 patients consented and 
were included
58 ablation, 
17 repeat radioiodine treatment
1 patient was excluded because of 
preparation for radioiodine treatment 
with rhTSH
7 patients were excluded because 
radioiodine therapy was cancelled*
67 patients were included for 
nal analysis
56 ablation
11 repeat treatment: 2nd (n = 9), 
3rd (n = 1), or 5th therapy (n = 1)
Figure 1 | Flowchart. * In one patient radioiodine ablation treatment was cancelled when a malignancy other than 
DTC was found after revision of the pathology report. In the remaining six patients repeat radioiodine therapy was 
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Table 1 | Baseline characteristics of DTC patients with paired measurements included for final analyses, and all 
patients initially included.
Patients with paired measurements All included patients 
(n = 67) (n = 75)
Age (years) mean±SD 47.7 ± 17.1 48.6±17.2
Female sex n (%) 42 (62.7) 46 (61.3)
Histology n (%)
Papillary 54 (80.6) 58 (77.3)
Follicular 7 (10.4) 10 (13.3)
Hürthle 6 (9.0) 7 (9.3)
TNM Tumor stage n (%)
T stage 
Tx-T2 41 (61.2) 45 (60.0)
T3 21 (31.3) 25 (33.3)
T4 5 (7.5) 5 (6.7)
N stage
Nx-N0 30 (44.8) 38 (50.7)
N1 37 (55.2) 37 (49.3)
M stage
Mx-M0 64 (95.5) 72 (96.0)
M1 3 (4.5) 3 (4.0)
Medications used at first study visit n (%)
Oral beta blockers 7 (10.4) 7 (9.3)
Diuretics 8 (11.9) 9 (12.0)
Neuropsychiatric drugs 8 (11.9) 10 (13.3)
Any ≥ 4 medications 23 (34.3) 26 (34.7)
Co-morbidity n (%)
Diabetes mellitus* 4 (6.0) 5 (6.7)
Hypertension* 16 (23.9) 18 (24.0)
Systemic diseases ** 2 (3.0) 2 (2.7)
Abbreviations: DTC = Differentiated Thyroid Carcinoma, SD = Standard Deviation.
* defined as documented treatment for these conditions, ** both patients had fibromyalgia
The majority of patients (88%) was treated with an activity of 5.55 GBq; cumulative radioiodine activities 
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Sialometry
In patients undergoing ablation therapy (n = 56), stimulated whole saliva flow rate decreased from 
0.92 [0.74 - 1.25] to 0.80 [0.58 - 1.18] ml/min (p = 0.003). Unstimulated whole-, and stimulated left 
and right parotid and submandibular flow rates decreased significantly as well (Table 2). In patients 
undergoing repeat radioiodine treatment (n = 11), stimulated whole saliva was 0.96 [0.45 - 1.31] before, 
and 0.53 [0.39 - 1.54] ml/min after treatment (p = 0.328). Unstimulated whole- and stimulated glandular 
flow rates did not significantly change either. Please refer to Supplemental Table 1 for an overview of 
sialometry reference ranges.
Table 2 | Salivary flow rates before and after radioiodine therapy.
Saliva flow rates of DTC patients (n = 67) Before treatment After treatment p-value
Ablation patients (n = 56)
Unstimulated whole saliva (n = 50) ml/min 0.44 [0.27 - 0.66] 0.33 [0.22 - 0.51] 0.009
Paraffin-stimulated whole saliva (n = 56) ml/min 0.92 [0.74 - 1.25] 0.80 [0.58 - 1.18] 0.003
Acid-stimulated left parotid saliva (n = 33) ml/min 0.10 [0.07 - 0.18] 0.09 [0.05 - 0.13] 0.027
Acid-stimulated right parotid saliva (n = 29) ml/min 0.10 [0.07 - 0.16] 0.06 [0.02 - 0.11] <0.001
Acid-stimulated SM saliva (n = 44) ml/min 0.33 [0.22 - 0.48] 0.31 [0.19 - 0.45] 0.044
Repeat therapy patients (n = 11)
Unstimulated whole saliva (n = 10) ml/min 0.32 [0.18 - 0.48] 0.26 [0.09 - 0.47] 0.169
Paraffin-stimulated whole saliva (n = 11) ml/min 0.96 [0.45 - 1.31] 0.53 [0.39 - 1.54] 0.328
Acid-stimulated left parotid saliva (n = 6) ml/min 0.26 [0.16 - 0.35] 0.14 [0.06 - 0.26] 0.249
Acid-stimulated right parotid saliva (n = 4) ml/min 0.19 [0.09 - 0.23] 0.20 [0.03 - 0.29] 0.715
Acid-stimulated SM saliva (n = 10) ml/min 0.47 [0.33 - 0.66] 0.25 [0.16 - 0.71] 0.059
Numbers (n) of patients with valid paired measurements (i.e. both a pre- and post-treatment measure were available of the same patient 
and salivary gland) are indicated for the particular flow-rate. Abbreviations: SM = submandibular.
There was a wide dispersion in baseline saliva flow-rates, and flow rate alterations post-treatment (Figure 
2 and Supplemental Figure 3). Of the total study population, 23 patients (34%) experienced a decrease of 
at least 25% in stimulated whole saliva flow rate, of which seven had a decrease of more than 50% (Figure 
2), A higher cumulative radioiodine activity, but not age, gender, tumor histology and TNM stage, was 
associated with a reduction in stimulated whole saliva flow rate of at least 50% (p = 0.026). 
Sialochemistry
Overall, clinically relevant differences were not observed in the pre- and post-radioiodine treatment 
salivary concentrations of sodium, potassium and chloride, while the output of total protein and amylase 
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Table 3 | Salivary composition of patients treated with ablation and repeat radioiodine therapy. 





Ablation patients (n = 56)
Total protein mg/min
Unstimulated whole saliva (n = 44) 0.18 [0.11 - 0.32] 0.15 [0.09 - 0.21] 0.031
Chewing-stimulated whole saliva (n = 56) 0.40 [0.27 - 0.61] 0.32 [0.20 - 0.46] 0.001
Acid-stimulated parotid saliva (n = 41) 0.05 [0.02 - 0.08] 0.03 [0.02 - 0.06] 0.101
Acid-stimulated SM (n = 49) 0.05 [0.02 - 0.08] 0.04 [0.02 - 0.07] 0.126
Amylase U/min
Unstimulated whole saliva (n = 44) 55.4 [27.9 - 111] 37.7 [19.1 - 78.6] 0.017
Chewing-stimulated whole saliva (n = 56) 161 [101 - 259] 116 [48.4 - 192] 0.006
Acid-stimulated parotid saliva (n = 37) 25.5 [11.0 - 46.7] 16.2 [7.4 - 30.0] 0.023
Acid-stimulated SM (n = 48) 11.7 [5.4 - 26.2] 10.5 [4.3 - 20.2] 0.028
Repeat treatment patients (n = 11)
Total protein mg/min
Unstimulated whole saliva (n = 9) 0.13 [0.06 - 0.38] 0.09 [0.06 - 0.27] 0.859
Chewing-stimulated saliva (n = 11) 0.33 [0.19 - 0.49] 0.26 [0.16 - 0.60] 0.424
Acid-stimulated parotid saliva (n = 7) 0.05 [0.02 - 0.11] 0.03 [0.01 - 0.09] 0.600
Acid-stimulated SM (n = 11) 0.06 [0.04 - 0.13] 0.03 [0.02 - 0.10] 0.021
Amylase U/min
Unstimulated whole saliva (n = 9) 37.3 [16.0 - 136] 20.8 [10.2 - 110] 0.028
Chewing-stimulated whole saliva (n = 11) 131 [90.6 - 187] 139 [6.4 - 266] 0.328
Acid-stimulated parotid saliva (n = 7) 28.9 [9.3 - 57.9] 20.7 [6.9 - 63.1] 0.463
Acid-stimulated SM (n = 11) 11.6 [7.0 - 48.2] 5.3 [3.6 - 51.6] 0.248
Numbers (n) of patients with valid paired measurements are indicated, dependent upon saliva quantity. Abbreviation: SM = submandibular 
gland saliva.
Xerostomia inventory
The score for ‘My mouth feels dry’ significantly increased after ablation (p = 0.001), albeit there was 
no significant increase in the total XI score (p = 0.064) (Supplemental Table 2). Two patients (4%) had 
xerostomia always or frequently before ablation treatment, as compared to 11 patients (20%) after 
therapy (Table 4). The pre- and post-therapy XI scores of patients receiving repeat therapy were similar. 
The post-therapy XI score was related to post-therapy stimulated whole saliva flow rate (Supplemental 
Figure 4).
Salivary gland radioiodine uptake on diagnostic scans
In Figure 3 a case is presented with clear accumulation of radioiodine in the salivary glands on the SPECT/
CT scan, which was performed 7 days after ablation therapy. Semi-quantitatively assessed radioiodine 
uptake in the parotid and submandibular glands on the pre- and post-therapy WBS did not correlate 
Processed on: 24-8-2016
504701-L-sub01-bw-Hesselink
94 | Chapter 6
with saliva flow rate alterations after radioiodine treatment (Supplemental Table 1). Quantitatively 
assessed uptake of radioiodine in the salivary glands (expressed in Bq and Bq/ml), did not correlate with 
alterations in saliva flow rates either (Supplemental Table 2).
Figure 2 | Displayed are changes in stimulated whole saliva flow rate for each of the 67 study subjects, ordered 
by basal flow rate. The lighter and paired darker bars represent flow rates before and after radioiodine treatment, 
respectively. The flow rate changes are color coded – green bars for subjects with less than 25% decrease, orange 
for 25 - 50% decrease, and red for > 50% decrease in stimulated whole saliva flow rate. 
Figure 3 | Uptake of radioiodine in the parotid (left panel) and submandibular (right panel) glands on the SPECT-
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Table 4 | Numbers of patients treated with radioiodine ablation and repeat treatment who indicated several 
extents of xerostomia before and after treatment.
Response to the question: 
My mouth feels dry
Ablation treatment (n = 56) Repeat treatment (n = 11)
Before therapy  
n (%)
After therapy  
n (%)
Before therapy  
n (%)
After therapy  
n (%)
Never 19 (34) 9 (16) 3 (27) 3 (27)
Hardly ever 18 (32) 20 (36) 0 2 (18)
Occasionally 17 (30) 16 (29) 5 (46) 3 (27)
Frequently 2 (4) 7 (13) 2 (18) 3 (27)
Always 0 4 (7) 1 (9) 0
DISCUSSION
In the current prospective study we found a decreased salivary gland function in DTC patients five months 
after high-activity radioiodine ablation therapy with endogenous TSH stimulation, as compared to pre-
ablation. Salivary flow rates decreased, the lowered output of amylase indicated acinar dysfunction, and 
patients had an increased subjective feeling of a dry mouth after ablation therapy. Overall xerostomia 
related morbidity was limited though, and salivary gland dysfunction was not a universal problem as 
there was a wide dispersion in flow rate alterations after radioiodine treatment. We did not find evidence 
for sialoadenitis five months post-treatment, as the concentration of salivary electrolytes was not altered. 
Uptake of radioiodine in the salivary glands on diagnostic scans did not correlate to flow rate alterations 
post-treatment, and in the small group of patients who underwent repeat treatments no alterations in 
salivary parameters were found.
 Previous studies on sialometry analyses in DTC patients are scarce. In one prospective study, parotid 
saliva composition alterations that correspond to an acute sialoadenitis were found one week after 
radioiodine treatment,14 whereas two cross-sectional studies on long-term effects of radioiodine 
treatment on whole saliva flow rates in DTC patients showed contradictory results.17,18 Studies using 
salivary gland scintigraphy, which assesses both the uptake and the excretion ability of the gland, are 
more abundant.12,13,19 In most studies an affected gland function was found after radioiodine therapy,12,19 
although in a recent paper this was found only after activities higher than 5.55 GBq.13 
 It is hard to precisely indicate the percentage of DTC patients who suffer from salivary gland damage 
after radioiodine treatment, as a uniform definition of this condition is lacking. A decrease of more than 
50% in saliva flow rate is generally regarded as the critical value for initiation of oral complaints.20 Ten 
percent of patients had such a decrease in stimulated whole saliva flow rate after radioiodine treatment. 
Approximately one third of patients had a decrease of at least 25%, which could already be relevant to 
this population since baseline saliva flow rates were rather low.20 The latter can possibly be explained 
by the gradually increasing hypothyroid state following endogenous TSH stimulation, which has been 
associated with reduced saliva secretion.21 Although study visits took place at least one week prior to 
radioiodine therapy to limit the effect of hypothyroidism, it may still have affected baseline saliva flow 
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rates. Other factors like medication use,22 or increased emotional stress after DTC diagnosis,23 may also 
have contributed to rather low baseline saliva secretion rates. Despite this, we were still able to find 
a decrease in flow rates at the second study visit when patients were in a euthyroid or (subclinical) 
hyperthyroid state due to thyroid hormone substitution, which emphasizes the adverse effects of 
radioiodine on saliva secretion. 
 The subjective feeling of a dry mouth increased after ablation therapy, although xerostomia-related 
morbidity was still limited. This may be explained by the finding that only seven patients experienced 
a decrease in stimulated whole saliva flow rate of more than 50% that generally results in xerostomia.20 
However, a decrease in stimulated saliva flow rate between 25 - 50% was common. This may progress 
and cause more pronounced oral complaints in case of further radioiodine treatment for high-risk 
patients. On the other hand, reversibility of salivary gland dysfunction is not precluded as a regenerative 
capacity for the parotid glands has been suggested based on data from patients treated with external 
radiotherapy for head and neck cancer.6
 We did not find convincing associations between radioiodine uptake in salivary glands on diagnostic 
planar and SPECT/CT scans and alterations in flow-rate of the particular glands, despite detailed 
evaluations of radioiodine uptake in salivary glands on several scans. Possibly, an explanation for this 
may be the non-dynamic nature of the scans,24 or a patient-specific regeneration capacity of the 
salivary glands. Altogether, these data indicate that it is hard to predict salivary gland dysfunction post-
radioiodine treatment using scans that are routinely performed. 
 A limitation of this study is that patients were assessed during different degrees of hypo- to 
hyperthyroidism at the two study visits, which may have influenced salivary gland function. Furthermore, 
we intended to evaluate the effects of repeat radioiodine therapy on salivary gland function as well, 
but within the inclusion period an insufficient number of patients underwent repeat therapy with 
endogenous TSH stimulation to gain sufficient statistical power. Unfortunately, extension of the inclusion 
period with several more years was not feasible. Additionally, we did not routinely record in all patients 
whether they had experienced clinical signs of acute and chronic sialoadenitis, and our secondary 
outcomes are less robust than our primary outcome, due to exclusion of several patients for especially 
glandular saliva flow rate analyses (which may have led to a selection of patients with normal baseline 
flow rates), and incomplete nuclear scan data. 
 In conclusion, salivary gland function is affected after radioiodine ablation therapy. Although 
overall morbidity was limited, and salivary gland dysfunction after a single high-activity of radioiodine 
treatment does not seem to be a universal problem, approximately 10% of patients experience a steep 
decline in stimulated whole saliva flow rate. Therefore, more emphasis should be placed on salivary 
gland dysfunction during DTC follow-up, and early referral to a dentist or oral medicine specialist should 
be considered when patients suffer from xerostomia-related complaints. This is especially important 
for patients at high risk for residual, recurrent or metastatic DTC who are expected to receive high-
activity radioiodine therapy repeatedly with endogenous TSH stimulation, and those with a pre-existent 
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